About Totient
Totient is a company based in Cambridge (United States) founded in 2017 by James Sietstra and Deniz Kural was acquired by AbSci in June 2021.. Totient has raised $10.5 million across 3 funding rounds from investors including AbSci, Viva Biotech and Viva BioInnovator. The company has 26 employees as of December 31, 2022. Totient operates in a competitive market with competitors including Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Cambridge, United States
- Employees 26 as on 31 Dec, 2022
- Founders James Sietstra, Deniz Kural
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Sbgd, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Totient
Totient has successfully raised a total of $10.5M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Last Round
-
First Round
First Round
(01 Mar 2019)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Seed - Totient | Valuation | CerraCap Ventures |
|
| Sep, 2020 | Amount | Seed - Totient | Valuation | Tau Ventures , Kaitai Capital Management | |
| Mar, 2019 | Amount | Seed - Totient | Valuation | Viva BioInnovator |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Totient
Totient has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include AbSci, Viva Biotech and Viva BioInnovator. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage tech companies in Asia and the US are funded.
|
Founded Year | Domain | Location | |
|
Seed-stage startups are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Kaitai Capital is engaged in innovation investment management services.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Totient
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Totient
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Totient Comparisons
Competitors of Totient
Totient operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Totient
Frequently Asked Questions about Totient
When was Totient founded?
Totient was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Where is Totient located?
Totient is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Totient?
Deniz Kural is the current CEO of Totient. They have also founded this company.
Is Totient a funded company?
Totient is a funded company, having raised a total of $10.5M across 3 funding rounds to date. The company's 1st funding round was a Seed of $500K, raised on Mar 01, 2019.
How many employees does Totient have?
As of Dec 31, 2022, the latest employee count at Totient is 26.
What does Totient do?
Developer of a drug discovery platform for cancer and autoimmune disease using artificial intelligence. The company uses immunoinformatics-algorithms, machine learning techniques, and tertiary lymphoid structures (TLS) for the identification of novel tissue-specific antigens and antibodies expressed by the cancer-affected tissues. The company develops cancer therapeutics by reconstructing antibodies from tissues affected by autoimmunity, infections, and cancer. The company has developed antibodies against novel extracellular oncology targets that include GAGE1, GAGE2A, LIVIN (BIRC7), PCNA, ANXA1, C4BPB, HCLS1, GPR83, and IL14A.
Who are the top competitors of Totient?
Totient's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
Who are Totient's investors?
Totient has 9 investors. Key investors include AbSci, Viva Biotech, Viva BioInnovator, CerraCap Ventures, and Tau Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.